JPRN-UMIN000008686招募中1 期
The Effect of Febuxostat on the Patient with Hyperuricemia and Non-alcoholic Steatohepatitis - Hyperuricemia and Non-alcoholic Steatohepatitis
Kanazawa University Graduate School of Medical Science, Disease Control and Homeostasis0 个研究点目标入组 130 人开始时间: 2012年8月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients should be excluded; 1. Infected with HBV or HCV 2. Alcohol assumption per day; greater than or equal to 30g for male, 20g/day for female 3. Accompanied with obvious malignant diseases including hepatoma 4. Accompanied with obvious hepatic encephalopathy 5. Accompanied with active infectious diseases (body temperature; higher or equal to 38 degree) 6.Accompanied with severe complications such as paralysis of intestine, ileus, interstitial pneumonia, pulmonary fibrosis, poorly controlled diabetes mellitus, heart failure, renal failure, liver failure, active ulcer and risky varix of digestive tract, and severe mental disturbance or depression etc. 7. Nursing woman and pregnant woman or the woman who may be pregnant 8. Taking contraindicating medicines with Febuxostat, such as mercaptopurine-hydrate, azathioprine, vidarabine, or didanosine. 9. Taking the following medicines which could affect serum uric acid within 4 weeks before considering entry of this study; losartan, fenofibrate, loop diuretic, or thiazide diuretic. 10. Taking the following uric acid-lowering medicines within 4 weeks before considering entry of this study; allopurinol, benzbromarone, probenecid, bucolome, or febuxostat. 11. Taking salicylated medicines everyday, however, the patients taking low dose of aspirin salicylate (less than or equal to 324 mg/day) cannot be excluded. 12.Taking estrogenic hormone everyday. 13. The other patients who the doctors in charge consider should not enter this study.
研究者
相似试验
已完成
不适用
Study of the effects of febuxostat in patients with diabetic nephropathy.Diabetic nephropathyJPRN-UMIN000015547Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine50
已完成
不适用
A study to evaluate the effect of febuxostat in heart failure patients with hyperuricemiaHeart failureJPRN-UMIN000021919Kochi Medical School, Kochi University200
已完成
不适用
Effect of Febuxostat on vascular function in patients with hyperuricemiahyperuricemiaJPRN-UMIN000009468agasaki University Graduate School of Biomedical Sciences Department of Cardiovascular Medicine30
招募中
3 期
the effect of febuxostat in sepsisIRCT20230814059148N1Tabriz University of Medical Sciences40
已完成
不适用
The efficacy of febuxostat or topiroxostat on nephropathy in type 2 diabetes with hyperuricemia: A randomized clinical trialType 2 diabetes with hyperuricemiaJPRN-UMIN000031708Yokohama City University120